LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker ...
Simon Spichak finished his MSc at University College Cork, where he studied the interactions between the microbes in the gut and the brain. He became interested in science communication during his ...
CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback